By Walt Hickey Cystic Fibrosis The results of a successful drug trial published Thursday led to the announcement of a new cystic fibrosis therapy that could benefit 90 percent of patients with the disease, and the FDA is so persuaded by the results they’ve already approved the three-drug combo called Trikafta well ahead of the deadline. It’s a massive advance over previous drugs to treat cystic fibrosis and the product is the result of thirty years of incremental scientific work. Cystic fibrosis affects 30,000 people in the U.S., and patients born today live on average 44 years thanks to existing therapies. The largest trial of Trikafta found improvements in lung function, decreases in hospitalizations and an increase in quality of life. It will cost $311,000 per year — drugs for small patient populations are typically very pricey — but doctors are optimistic insurers will cover it.